Literature DB >> 7719188

What constitutes good prescribing?

N Barber1.   

Abstract

Drugs are the mainstay of medical treatment, yet there are few reports on what constitutes "good prescribing." What is more the existing guidance tends to imply that right answers exist, rather than recognising the complex trade offs that have to be made between conflicting aims. This paper proposes four aims that a prescriber should try to achieve, both on first prescribing a drug and on subsequently monitoring it. They are: to maximise effectiveness, minimise risks, minimise costs, and respect the patient's choices. This model of good prescribing brings together the traditional balancing of risks and benefits with the need to reduce costs and the right of the patient to make choices in treatment. The four aims are shown as a diagram plotting their commonest conflicts, which may be used as an aid to discussion and decision making.

Entities:  

Mesh:

Year:  1995        PMID: 7719188      PMCID: PMC2549298          DOI: 10.1136/bmj.310.6984.923

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  4 in total

1.  THE DESIGN AND LOGIC OF A MONITOR OF DRUG USE.

Authors:  D J FINNEY
Journal:  J Chronic Dis       Date:  1965-01

2.  Physician motivations for nonscientific drug prescribing.

Authors:  R K Schwartz; S B Soumerai; J Avorn
Journal:  Soc Sci Med       Date:  1989       Impact factor: 4.634

3.  Adverse drug reactions. A critical review.

Authors:  F E Karch; L Lasagna
Journal:  JAMA       Date:  1975-12-22       Impact factor: 56.272

Review 4.  Decision making and prescribing patterns--a literature review.

Authors:  C P Bradley
Journal:  Fam Pract       Date:  1991-09       Impact factor: 2.267

  4 in total
  33 in total

1.  Implementing a multiple-isolator unit for centralized preparation of cytotoxic drugs in a cancer center pharmacy.

Authors:  J L Cazin; P Gosselin
Journal:  Pharm World Sci       Date:  1999-08

2.  Reconfiguring professional ethics: the rise of managerialism and public health in the UK National Health Service.

Authors:  A Cribb
Journal:  HEC Forum       Date:  2001-06

3.  The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.

Authors:  R M Martin; N R Dunn; S Freemantle; S Shakir
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

4.  Prescribers, patients and policy: the limits of technique.

Authors:  A Cribb; N Barber
Journal:  Health Care Anal       Date:  1997-12

5.  A qualitative study to explore influences on general practitioners' decisions to prescribe new drugs.

Authors:  Ann Jacoby; Monica Smith; Martin Eccles
Journal:  Br J Gen Pract       Date:  2003-02       Impact factor: 5.386

6.  Explanatory model of prescribing behavior in prescription of statins in family practice.

Authors:  Ksenija Tusek-Bunc; Janko Kersnik; Marija Petek-Ster; Davorina Petek; Zalika Klemenc-Ketis
Journal:  Wien Klin Wochenschr       Date:  2010-05       Impact factor: 1.704

7.  Indicators of prescribing quality in drug utilisation research: report of a European meeting (DURQUIM, 13-15 May 2004).

Authors:  J L Hoven; F M Haaijer-Ruskamp; R H Vander Stichele
Journal:  Eur J Clin Pharmacol       Date:  2004-12-09       Impact factor: 2.953

8.  Understanding adherence to official guidelines on statin prescribing in primary health care--a multi-level methodological approach.

Authors:  H Ohlsson; U Lindblad; T Lithman; B Ericsson; U-G Gerdtham; A Melander; L Råstam; J Merlo
Journal:  Eur J Clin Pharmacol       Date:  2005-10-19       Impact factor: 2.953

9.  Factor analysis improves the selection of prescribing indicators.

Authors:  Hanne Marie Skyggedal Rasmussen; Jens Søndergaard; Ineta Sokolowski; Jens Peter Kampmann; Morten Andersen
Journal:  Eur J Clin Pharmacol       Date:  2006-10-06       Impact factor: 2.953

10.  Factors involved in deciding to start preventive treatment: qualitative study of clinicians' and lay people's attitudes.

Authors:  David K Lewis; Jude Robinson; Ewan Wilkinson
Journal:  BMJ       Date:  2003-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.